- Home
- RDI vs ALGS Comparison
RDI vs ALGS Comparison
Compare RDI & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- ALGS
- Stock Information
- Founded
- RDI 1937
- ALGS 2018
- Country
- RDI United States
- ALGS United States
- Employees
- RDI N/A
- ALGS N/A
- Industry
- RDI Movies/Entertainment
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- ALGS Health Care
- Exchange
- RDI Nasdaq
- ALGS Nasdaq
- Market Cap
- RDI 30.1M
- ALGS 32.4M
- IPO Year
- RDI N/A
- ALGS 2020
- Fundamental
- Price
- RDI $1.33
- ALGS $4.48
- Analyst Decision
- RDI Hold
- ALGS Strong Buy
- Analyst Count
- RDI 1
- ALGS 1
- Target Price
- RDI $2.40
- ALGS $70.00
- AVG Volume (30 Days)
- RDI 33.3K
- ALGS 134.4K
- Earning Date
- RDI 05-19-2025
- ALGS 05-06-2025
- Dividend Yield
- RDI N/A
- ALGS N/A
- EPS Growth
- RDI N/A
- ALGS N/A
- EPS
- RDI N/A
- ALGS N/A
- Revenue
- RDI $210,527,000.00
- ALGS $3,270,000.00
- Revenue This Year
- RDI $9.74
- ALGS $580.86
- Revenue Next Year
- RDI $6.39
- ALGS N/A
- P/E Ratio
- RDI N/A
- ALGS N/A
- Revenue Growth
- RDI N/A
- ALGS N/A
- 52 Week Low
- RDI $1.17
- ALGS $3.76
- 52 Week High
- RDI $1.89
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- RDI 52.82
- ALGS 35.72
- Support Level
- RDI $1.23
- ALGS $4.20
- Resistance Level
- RDI $1.30
- ALGS $6.35
- Average True Range (ATR)
- RDI 0.07
- ALGS 0.66
- MACD
- RDI 0.01
- ALGS 0.24
- Stochastic Oscillator
- RDI 50.00
- ALGS 13.02
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.